Overview

Assessing SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Status:
Not yet recruiting

Trial end date:
2023-08-15

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of depression and suicidality in adults with Major Depressive Disorder who are at imminent risk for suicide.

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

Seelos Therapeutics, Inc.

Treatments:

Ketamine